Abstract: A composition of chlorogenic acids and method of its use and manufacture in the treatment of metabolic disorders. The composition can be obtained from sunflower seed extract, including Helianthus annulus seeds.
Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
Abstract: Provided herein is 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate or pharmaceutically acceptable salts thereof. Furthermore, for use and methods in the treatment of various pains and inflammation, in particular osteoarthritis with pharmaceutical compositions, treatment kits and devices comprising 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate and/or pharmaceutically acceptable salts thereof, as well as dosage forms, dosages, and methods of use thereof through topical administration, for treatment of various pains and inflammation, in particular osteoarthritis, are disclosed.
Abstract: The present patent application relates to O-acetylserine, or a salt or derivative thereof, for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual. The invention also relates to a composition for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual, comprising an O-acetylserine, or a salt or derivative thereof, and a physiologically acceptable vehicle.
Abstract: Compositions and methods for improving cardiac structure and/or function in subjects in need thereof. The methods include administering to a subject a succinate dehydrogenase inhibitor in an amount and for a time effective to elicit an improvement in cardiac structure and/or function. The subjects include subjects suffering from cardiac damage, such as damage resulting from myocardial infarction or other cardiac events. Improvements in cardiac function include one or more of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, and a decrease in left ventricle internal diameter systole. Improvements in cardiac structure include one or more of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, and a decrease in myocardial lesion size.
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Type:
Application
Filed:
February 24, 2023
Publication date:
January 25, 2024
Inventors:
Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
Abstract: The present invention concerns compositions containing ranitidine or one of its pharmaceutically acceptable salts having low iron species content. The present invention also concerns compositions having low content of iron species that are not under complexed form with a chelating agent and/or having low content of iron species that are partially or completely under complexed form with a chelating agent and/or having low content of iron species that are under complexed form with a chelating agent other than ranitidine and/or having low content of complexes formed between ranitidine and iron species. The present invention also concerns a process for the preparation of said compositions. The present invention also concerns the second medical use of said compositions.
Abstract: Provided herein are methods of reducing the weight loss and/or increasing the weight of a feline in need thereof, said methods include administering to a feline in need thereof a total daily dosage of about 2 to 50 mg of Compound 1, having the formula: or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing the disease of a feline with diabetes mellitus and elevated IGF-1 concentration.
Abstract: A senotherapeutic substance including flavonoids, fatty acids, and, preferably, phenolic acids and/or vitamins. The substance may be used for the manufacture of a medicament for senotherapeutic use.
Type:
Application
Filed:
November 30, 2021
Publication date:
January 25, 2024
Inventors:
Venera RUSSO, Giovanni Mario PITARI, Claudia Giovanna LEOTTA, Mario CORREALE, Paolo CORREALE
Abstract: The present invention relates to a method for treating a subject suffering from a liver disease comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of the endoribonuclease activity of IRE1?. Inventors have shown that in livers of tunicamycin-treated BI-1?/? mice aIRE1?-dependent NLRP3 inflammasome activation, an hepatocyte death, a fibrosis and a dysregulated lipid homeostasis that led to liver failure within a week. To test whether the pharmacological inhibition of IRE1? endoribonuclease activity would block the transition to NASH, mice were injected with the small molecule STF-083010 twice a week for 2 weeks towards the end of a 3-month HFD. In BI-1?/? mice, STF-083010 treatment effectively counteracted IRE1? endoribonuclease activity, improving glucose tolerance and rescuing from NASH.
Type:
Application
Filed:
June 2, 2023
Publication date:
January 25, 2024
Inventors:
Beatrice BAILLY-MAITRE RE, Philippe GUAL, Albert TRAN
Abstract: The present invention relates to a product which is C-phycocyanin or an extract comprising C-phycocyanin; or alternatively, to compositions comprising said product and one or more pharmaceutically acceptable excipients or carriers, for use in the treatment and/or prevention of peripheral neuropathy.
Type:
Application
Filed:
September 21, 2021
Publication date:
January 25, 2024
Inventors:
Consuelo SAN GABRIEL ALCOLEA, Pere GASCÓN VILAPLANA, Emmanuel BLUM
Abstract: A pharmaceutical composition contains Indomethacin. In particular, the composition is a suppository containing a hard fat as a base material.
Type:
Application
Filed:
July 12, 2023
Publication date:
January 25, 2024
Applicant:
FULTON MEDICINALI S.P.A.
Inventors:
Alessandro GALLI, Simone SARNO, Claudio BELLONI, Antonio GERMANI
Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
Type:
Application
Filed:
August 1, 2023
Publication date:
January 25, 2024
Inventors:
Sadasivan VIDYASAGAR, Paul OKUNIEFF, Lurong ZHANG
Abstract: An application of Anle138b in a drug for improving diet-induced insulin resistance is provided. Anle138b has obvious improvement effects on both preventing and treating insulin resistance, and can reduce the intake efficiency and the body weight. Besides, Anle138b can effectively improve diet-induced ectopic fat storage and adipose tissue hypertrophy, and the effect of Anle138b on improving insulin resistance is independent of the reduction of food intake.
Type:
Application
Filed:
October 28, 2022
Publication date:
January 25, 2024
Applicant:
The First Affiliated Hospital of Shantou University Medical College
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Type:
Application
Filed:
July 17, 2020
Publication date:
January 25, 2024
Inventors:
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART, Lavanya RAJACHANDRAN, Robert RISINGER
Abstract: Disclosed herein are methods and composition for treating bipolar disorders and psychosis by administering dexmedetomidine. The methods and composition alleviate mania, hypomania, psychosis, and depression in the subjects, providing improved therapeutic outcomes.
Type:
Application
Filed:
October 8, 2021
Publication date:
January 25, 2024
Inventors:
Frank YOCCA, Robert RISINGER, Michael DE VIVO, Friso POSTMA
Abstract: The present disclosure relates to pharmaceutical compositions comprising Compound I, or a pharmaceutically acceptable salt thereof, as the active substance. The pharmaceutical compositions are suitable for use in immediate release pharmaceutical formulations. The pharmaceutical formulations are suitable for use in the treatment of medical conditions in which treatment with agonists of CB1/CB2 receptors are beneficial.
Type:
Application
Filed:
July 12, 2021
Publication date:
January 25, 2024
Applicant:
ARTELO BIOSCIENCES LIMITED
Inventors:
Andrew YATES, Paul DICKINSON, Robert WARD
Abstract: Provided herein are methods for treating brain cancers, such as malignant gliomas, particularly glioblastomas. Inhibitors of dihydroorotate dehydrogenase singly or in combination with at least other one small molecule drug acting synergistically with the dihydroorotate dehydrogenase inhibitor are administered to a subject with a brain cancer or brought into contact with brain cancer tumor cells. Administration of a drug regimen of the inhibitor and at least one of the small molecule drugs increases sensitivity of a malignant glioma thereto.
Abstract: Congenital aniridia is a rare and severe genetic panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% cases is caused by PAX6 haploinsufficiency. Ataluren eye-drops aim to restore ocular surface PAX6 haploinsufficiency in Aniridia Related Keratopathy (ARK). However, they are currently no ophthalmic solution available forms. The objective of this study was to assess the physicochemical and microbiological stability of ataluren eye-drop 1% in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient.
Abstract: The present application relates to methods for treatment of Rett syndrome comprising administering an effect amount of nomethiazoles to a subject need thereof.
Abstract: The disclosure provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered atosiban in combination with a prostaglandin F2? (PGF2?) antagonist. Exemplary PGF2? receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride). The compositions and methods described herein provide various clinical benefits.
Abstract: A method for inhibiting hair growth in mammals using compositions containing thiazoiidine or quinoline carboxamide FP receptor antagonists. The compositions can be applied topically to the skin and/or hair. The compositions can (1) arrest hirsutism or hypertrichosis, (2) reverse hirsutism, hypertrichosis, and/or unwanted hair, and (3) prevent or limit hair growth including after hair removal by chemical or physical methods. These compositions can also be used to help prevent or to limit the degree of hair loss from chemotherapy/cytotoxic chemical agents or radiation.
Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
Abstract: A method for preventing or treating renal ischemia reperfusion injury or acute kidney injury associated with renal ischemia reperfusion injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Type:
Application
Filed:
March 29, 2023
Publication date:
January 25, 2024
Inventors:
Sanford Markowitz, Ki Beom Bae, Hye Jung Kim, Sun-Hee Kim
Abstract: Disclosed are methods and compositions for treating a human papillomavirus (HPV)-related disease or cancer in an individual in need thereof. The method may comprise administering a glucosylceramide synthase (GCS) inhibitor to the individual, for example, miglustat, eligustat, venglustat, T-036, and combinations thereof. The disclosed methods and compositions may be used to treat cancers such as cervical cancer, oropharyngeal cancer, vulvar cancer, anal cancer, penile cancer, vaginal cancer, rectal cancer, squamous cell carcinoma, adenocarcinoma, head and neck cancer, or skin or mucosal lesions such as a common wart, a genital wart, a respiratory wart, a plantar wart, a subungual wart, a periungual wart, a flat wart, and combinations thereof.
Type:
Application
Filed:
July 21, 2023
Publication date:
January 25, 2024
Inventors:
Susanne Wells, Taylor Lange, Kanimozhi Vairamani
Abstract: The spleen clears rigid erythrocytes from the circulation. Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria By screening 13 555 compounds with spleen-mimetic microfilters, the inventors identified 82 compounds that stiffen mature gametocytes. Eight active families were identified, including known anti-malarial, antimicrobial or anticancer agents, amongst others. Hit prioritization based on accessible safety and pharmacokinetics data in humans identified 3 leading candidates. NITD609 displayed killing and stiffening effects (IC50 of 100 and 50 nM, respectively), while TD-6450 and L-THP had a pure or predominant stiffening effect (IC50 of 600 and 5 nM, respectively). These values are lower than or close to peak plasma concentrations in humans. Clinical trials with these strong malaria transmission-blocking candidates are envisioned.
Type:
Application
Filed:
December 13, 2021
Publication date:
January 25, 2024
Inventors:
Pierre BUFFET, Papa Alioune NDOUR, Mario CARUCCI, Julien DUEZ
Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
Abstract: Provided herein are methods of tipifarnib in combination with a PI3K inhibitor, such as alpelisib, for treating, preventing or managing head and neck squamous cell carcinoma (HNSCC).
Type:
Application
Filed:
July 20, 2023
Publication date:
January 25, 2024
Inventors:
Francis Burrows, Mollie Leoni, Shivani Malik, Vishnu S. Mishra, Alison Smith, Harris Soifer
Abstract: Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R1, R2, R3, n, R4, R4a, R5, m, R6, R7, and p are as defined herein.
Type:
Application
Filed:
October 25, 2021
Publication date:
January 25, 2024
Inventors:
Jeffrey E. SAFFITZ, Bruce D. HAMMOCK, Sung Hee HWANG
Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.
Abstract: Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.
Type:
Application
Filed:
February 16, 2023
Publication date:
January 25, 2024
Inventors:
Laura Corradini, Sam Jackson, Karoly Nikolich
Abstract: The present disclosure relates to a process for preparing arimoclomol, arimoclomol citrate and key intermediates, such as ORZY-01, thereof. The disclosure further relates to a process for preparing high purity arimoclomol citrate and methods of using the same.
Type:
Application
Filed:
May 31, 2023
Publication date:
January 25, 2024
Inventors:
Zhe ZHANG, Mark READ, Elisabeth Vang CARSTENSEN, Marco POPPE, Andreas PELZ
Abstract: A combination in only one dosage unit the drugs desloratadine and betamethasone, which represents a set of important technological challenges due to the physicochemical properties and the difference in dosage to ensure the obtaining of a stable product for the treatment of allergic and inflammatory processes in a subject.
Abstract: TLR7/8 antagonists can be used to treat coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
Abstract: A controlled release pharmaceutical dosage form that improve tolerability by reducing incidence of side effect associated with a Selexipag or its active metabolite contained in the dosage form comprising a release rate controlling ingredient in addition to the Selexipag or its active metabolite that govern a release of the Selexipag or its active metabolite from the dosage form, wherein the dosage form after administration to a mammal in fasting condition providing a. a mean or median Tmax of at least greater than 2 hours for the Selexipag and/or at least greater than 3.5 hours for the active metabolite of the Selexipag, and/or b. at least 20% lower Cmax for Selexipag and/or it's active metabolite compared to Cmax obtained after administration of the same amount of an immediate release dosage form of Selexipag or its active metabolite in fasting condition.
Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof. It also relates to controlling nitrosamine impurity, 7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP) in the composition, wherein the NTTP does not exceed the FDA's established acceptable intake limit of 0.37 ppm per day at release and during shelf-life.
Abstract: The disclosure is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. The disclosure is also directed to pharmaceutical compositions containing compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof, and uses of the pharmaceutical compositions in treating diseases, conditions, and disorders associated with fatty acid amide hydrolase (FAAH) activity.
Type:
Application
Filed:
July 17, 2023
Publication date:
January 25, 2024
Inventors:
Ju SHI, Sheryl COPPOLA, Polly Rae PINE, Matthew BOYLAN, Thomas Wesley STOREY
Abstract: Therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating splenomegaly using a BTK inhibitor.
Abstract: The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
Type:
Application
Filed:
April 3, 2023
Publication date:
January 25, 2024
Applicant:
NewAmsterdam Pharma B.V.
Inventors:
John FORD, Patrick ROUND, John KASTELEIN, Atsuhiro KAWAGUCHI, Koichi TOMIYASU, Kozo OKA
Abstract: There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.
Type:
Application
Filed:
January 4, 2023
Publication date:
January 25, 2024
Inventors:
Magdalena Alonso-Galicia, David Carpenter, Thomas Pack, Melissa Rhodes, Julie Rurka, Stephen Wring
Abstract: The present invention is directed to a combination treatment using bosentan and a checkpoint inhibitor that is effective in treating cancer or inhibiting the proliferation of tumor cells in a subject and/or that can initiate, enhance or prolong the immune response to tumor cells.
Type:
Application
Filed:
December 9, 2021
Publication date:
January 25, 2024
Inventors:
John D. MARTIN, Triantafyllos STYLIANOPOULOS, Fotios MPEKRIS, Myrofora PANAGI, Chysovalantis VOUTOURI, Andreas STYLIANOU
Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.